Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Waldencast (NASDAQ: WALD) announced it will file a Form 12b-25 with the SEC for a 15-day extension to submit its Annual Report for the fiscal year ending December 31, 2022. This delay stems from an ongoing review of year-end financial statements, particularly regarding accounting issues related to the sale of Obagi products in Vietnam. The Audit Committee is conducting an independent review to determine necessary adjustments. Additionally, Waldencast completed a 60% acquisition of its Southeast Asia distributor, clearing some accounts receivable while retaining rights to future payments. The company is also assessing internal accounting controls, facing potential challenges with the Annual Report's filing and lender engagements due to the ongoing review.
Waldencast has announced a binding letter of intent to acquire a 60% controlling interest in a newly formed entity from its Southeast Asia distributor. This acquisition targets the rapidly growing $11 billion skincare market in Southeast Asia, with the Obagi brand expected to experience accelerated growth. The deal is contingent upon due diligence and definitive agreements, with completion anticipated in the coming weeks. Additionally, Waldencast has rescheduled its fourth quarter fiscal 2022 earnings call to April 26, 2023, to assess potential adjustments in financials relating to the acquisition.
Waldencast plc (NASDAQ: WALD) announced a conference call to discuss its fourth quarter 2022 earnings results, scheduled for March 15, 2023, at 8:30 AM ET. The earnings press release will be available before the call. Investors can join the call by dialing toll-free numbers or via a live webcast accessible on Waldencast's investor relations website. The company aims to establish a leading beauty and wellness platform, leveraging its brand-led business model and operational scale to enhance brand performance and customer engagement. More details can be found on their official website.
Waldencast, a global beauty and wellness platform (NASDAQ: WALD), announced its participation in key consumer conferences in March 2023. The Company will present at the Raymond James 44th Annual Institutional Investors Conference on March 6 at 1:05 p.m. EST in Orlando, Florida, and at the D.A. Davidson 6th Annual Consumer Conference on March 21 at 11:45 a.m. EST in New York City. CEO Michel Brousset will lead both events, which will be webcast and available for replay. Waldencast aims to develop and scale purpose-driven beauty brands, following its recent combination with Obagi Skincare and Milk Makeup.
Waldencast plc (NASDAQ: WALD) announced its participation in the 25th Annual ICR Conference on January 9, 2023, at 10:30 a.m. EST. CEO Michel Brousset will partake in a fireside chat, available live and on replay via the company's Investor Relations page. The firm aims to establish a leading global beauty and wellness platform through the development and scaling of purpose-driven brands.